Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: J Thorac Oncol. 2016 Feb 23;11(6):838–849. doi: 10.1016/j.jtho.2016.02.009

Table 1.

Measures of test performance between the STK11 signature and detected DNA variation in TCGA and the MLOS cohorts

Detected DNA
Variation
Signature
Prediction
N Class Metric Value 95% CI
TCGA
Mutant STK11+ 71 TP (True Positives) Sensitivity 0.947 (0.869, 0.985)
Mutant WT 4 FN (False Negatives) Specificity 0.732 (0.686, 0.77)
WT STK11+ 109 FP (False Positives) Precision 0.394 (0.322, 0.469)
WT WT 298 TN (True Negatives) NPV (Negative Predictive Value) 0.987 (0.966, 0.996)
False Positive Rate 0.268 (0.22, 0.313)
False Discovery Rate 0.606 (0.53, 0.677)
MLOS
Mutant STK11+ 66 TP (True Positives) Sensitivity 0.971 (0.897, 0.996)
Mutant WT 2 FN (False Negatives) Specificity 0.741 (0.693, 0.784)
WT STK11+ 97 FP (False Positives) Precision 0.405 (0.328, 0.484)
WT WT 277 TN (True Negatives) NPV (Negative Predictive Value) 0.993 (0.974, 0.999)
False Positive Rate 0.259 (0.215, 0.306)
False Discovery Rate 0.595 (0.515, 0.671)